Sarepta Therapeutics Inc (SRPT)

Return on total capital

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	53,913	-498,088	-638,311	-852,048	-1,054,752	-636,715	-647,938	-438,168	-292,031	-355,423	-419,337	-569,939	-641,098	-493,118	-549,965	-486,033	-617,749	-683,211	-591,034	-538,838
Long-term debt	US$ in thousands	1,133,660	1,132,520	1,236,760	1,235,520	1,234,280	1,544,290	1,542,770	1,100,870	1,098,850	1,096,880	1,094,910	1,092,980	1,091,110	992,493	700,470	694,156	687,953	681,900	436,421	431,040
Total stockholders’ equity	US$ in thousands	961,192	859,337	764,357	741,411	712,749	384,950	430,840	726,457	856,886	928,009	469,528	485,108	535,445	761,759	892,047	1,042,870	1,144,830	818,187	995,204	1,099,170
Return on total capital		2.57%	-25.01%	-31.90%	-43.10%	-54.17%	-33.00%	-32.83%	-23.98%	-14.93%	-17.55%	-26.80%	-36.12%	-39.41%	-28.11%	-34.53%	-27.98%	-33.71%	-45.54%	-41.28%	-35.21%

March 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $53,913K ÷ ($1,133,660K + $961,192K)
= 2.57%

Sarepta Therapeutics Inc's return on total capital has shown fluctuating performance over the past few quarters. The return on total capital was positive at 2.57% in March 2024 but had been negative in the previous quarters, ranging from -25.01% to -54.17%. This indicates that the company's ability to generate returns from its total capital has been inconsistent and volatile.

The negative returns suggest that the company may be facing challenges in efficiently utilizing its capital to generate profits. It is important for Sarepta Therapeutics Inc to focus on improving its operational efficiency, cost management, and revenue generation strategies to enhance its return on total capital in the future. Further analysis of the company's financial and operational performance would be necessary to understand the key drivers behind these fluctuations and to develop appropriate strategies for improvement.